ALKS (Alkermes PLC) רווח נקי למניה אחת בשנים עשר החודשים האחרונים

Alkermes plc payout stability relies on patent expiration dates and government insurance. This chart of EPS YoY ttm growth rates confirms the model's resilience, where the -100.10 value serves as a baseline reliability indicator. The company's advantage lies in inelastic demand and unique drug delivery methods, while an active R&D pipeline in oncology and psychiatry ensures future growth.

This indicator measures the dynamics of net earnings per share over the last twelve months relative to the same period last year, reflecting the actual growth rate of return on equity. By comparing the history of EPS YoY (TTM) percentage changes with the quotes of Alkermes plc (ALKS), an investor assesses the efficiency of cost management, including strict compliance with environmental regulations and energy saving at pharmaceutical production facilities.